Evidence map›Paper›PMID 37278329›Full record

ArticlePharmacology research & perspectives2023

Syringin inhibits endogenous volume regulated anion channel currents of HEK293 cells in hypotonic circumstances.

Ziwei Xu, Wei Yao, Minyan Liang, Song Wang, Longhui Lu, Jingjing Wang, Na Zhu, Liping Huang

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ziwei XuSchool of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, P. R. China.ORCID https://orcid.org/0000-0002-8280-4314
Wei YaoSchool of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, P. R. China.
Minyan LiangSchool of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, P. R. China.
Song WangSchool of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, P. R. China.
Longhui LuSchool of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, P. R. China.
Jingjing WangSchool of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, P. R. China.
Na ZhuSchool of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, P. R. China.
Liping HuangSchool of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, P. R. China.ORCID https://orcid.org/0000-0002-8120-8342
Jiangxi University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Syringin is a natural chemical compound first isolated from the bark of lilac and is known to have neuroprotective effects in middle cerebral artery occlusion (MCAO). Volume regulated anion channel (VRAC) is a cell swelling-activated anion channel, which is implicated in brain ischemia. However, the mechanism underlying the syringin protecting the neuron from damage in MCAO is still unclear. We hypothesized that syringin has an inhibitory effect on the opening of VRAC channels. To access the effect of syringin on VRAC currents and predict how syringin interacts with VRAC proteins, we performed whole-cell patch-clamp experiments using HEK293 cells. Initially, HEK293 cells were perfused with isotonic extracellular solution, followed by hypotonic extracellular solution to stimulate endogenous VRAC currents. Once the VRAC currents reached a steady state, the hypotonic solution containing syringin was perfused to study the effect of syringin on VRAC currents. The potential interaction between syringin and the VRAC protein was investigated using molecular docking as a predictive model. In this study, we found that syringin moderately inhibited VRAC currents in a dose-dependent manner. The potential binding of syringin to LRRC8 protein was predicted through in silico molecular docking, which suggests an affinity of -6.6 kcal/mol and potential binding sites of arginine 103 and leucine 101. Our results herein characterize syringin as an inhibitor of the VRAC channels, which provides valuable insights for the future development of VRAC channel inhibitors.

Indexed as

Membrane ProteinsAnionsGlucosidesHEK293 CellsHumansMolecular Docking SimulationPhenylpropionatesAnionsGlucosidesMembrane ProteinsPhenylpropionatessyringininhibitormolecular dockingsyringinVRAC channels

Identifiers

PMID37278329
PMCPMC10242655
OpenAlexW4379509162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.